stockrowLiquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.
- Revenue
- +1,842.7%
- EPS
- +271.4%
- Free cash flow
- +270.2%
- Total debt
- −9.04%
Quarter to June 2026, against a year earlier
Follow LQDA
Alert me
Liquidia Corporation (LQDA) Return on assets
Liquidia Corporation's return on assets over the twelve months to 30 June 2026 was 35.6%, up 60.3 percentage points from fiscal 2025 (−24.7%). Over the past ten years it has ranged from −249.9% (fiscal 2017) to 0.00% (fiscal 2022); the current reading is higher than 69% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −1.67% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −24.7% | 48.90 |
| FY2024 | −73.6% | (10.16) |
| FY2023 | −63.4% | (26.63) |
| FY2022 | −36.8% | (36.80) |
| FY2022 | 0.00% | 35.78 |
| FY2021 | −35.8% | (35.78) |
| FY2021 | 0.00% | 70.99 |
| FY2020 | −71.0% | (70.99) |
| FY2020 | 0.00% | 80.47 |
| FY2019 | −80.5% | (80.47) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LQDA Liquidia Corporation | 35.6% |
| SUPN Indivior Pharmaceuticals Inc. compare | 32.8% |
| LNTH Lantheus Holdings, Inc. compare | 11.4% |
| PBH Prestige Consumer Healthcare Inc. compare | 3.80% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 3.01% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| HIMS Hims & Hers Health, Inc. compare | −5.16% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −66.3% |
| Drug Manufacturers Specialty & Generic industry median | −1.67% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on LQDA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement